Penile Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Penile cancer is a rare malignancy with an incidence of approximately 1 per 100,000 men in high-income countries, rising to 4–8 per 100,000 in parts of South America (Brazil, Uruguay), sub-Saharan Africa, and South-East Asia where circumcision rates are lower and HPV prevalence is higher. Squamous cell carcinoma (SCC) accounts for over 95% of penile cancers. HPV infection — particularly genotypes 16 and 18 — contributes to 40–50% of cases, while phimosis (tight foreskin preventing glans retraction), chronic balanoposthitis, lichen sclerosus, and tobacco use are established additional risk factors. Circumcision (neonatal in particular) is protective. Treatment is strictly stage-guided and has evolved substantially toward penile preservation, balancing oncological control against functional and psychosexual outcomes. For penile carcinoma in situ (CIS/Tis), topical treatments (imiquimod 5%, 5-fluorouracil cream) or laser ablation (CO2 or Nd:YAG) are highly effective. Low-grade T1a tumors are managed with glansectomy (glans resurfacing or full glansectomy with split-skin graft reconstruction) or wide local excision. Higher-grade T1b and T2 tumors with invasion into corpus spongiosum or cavernosum may require partial penectomy or radical penectomy depending on lesion location and surgical margin requirements. Inguinal lymph node management is one of the most critical prognostic determinants: dynamic sentinel lymph node biopsy (DSNB) is the standard staging procedure for clinically node-negative (cN0) patients with T1b–T3 primary tumors, and radical inguinal lymphadenectomy is performed for node-positive disease.

Penile cancer treatment encompasses the full spectrum of primary tumors and regional nodal disease. Penile carcinoma in situ (CIS) includes Bowen's disease (keratinizing SCC in situ of the penile shaft) and erythroplasia of Queyrat (non-keratinizing SCC in situ of the glans — higher malignant potential), both characterized by atypical cells confined to the epithelium without basement membrane invasion. Stage T1a tumors invade the subepithelial connective tissue without lymphovascular invasion or perineural invasion and are considered low-risk; T1b tumors have the same invasion depth but exhibit lymphovascular invasion, perineural invasion, or high-grade (grade 3) histology and carry significantly higher nodal metastasis risk (15–25% vs 2–5%). T2 tumors invade corpus spongiosum or cavernosum; T3 tumors involve the urethra; T4 tumors invade adjacent structures (scrotum, prostate, pubic bone). Inguinal nodal disease is staged as N1 (1–2 ipsilateral mobile nodes), N2 (3+ ipsilateral or bilateral mobile nodes), and N3 (fixed inguinal mass or pelvic nodes). Verrucous carcinoma (Buschke-Löwenstein tumor) — a large, locally aggressive but rarely metastasizing low-grade variant — is treated with wide excision. Recurrent penile SCC following prior organ-preserving surgery is managed with more radical resection.

Treatment selection is guided by tumor stage, grade, lymphovascular invasion status, and clinical node assessment. Penile CIS and low-grade T1a tumors are candidates for organ-preserving approaches: CO2 laser (superficial ablation) or Nd:YAG laser (deeper penetration, suitable for invasive CIS), topical imiquimod (12–16 week course), or glansectomy with split-skin graft. The criteria for organ preservation in T1b–T2 are disease-free surgical margins achievable while maintaining functional length. Glansectomy with skin graft reconstruction achieves local control in 85–90% of T1 glans tumors. Partial penectomy is required when the tumor location or size does not allow adequate resection with preservation of function. Total penectomy with perineal urethrostomy is reserved for T3–T4 disease or proximal shaft tumors. Inguinal node staging via DSNB is indicated for cT1b–T3 N0 patients at centers with DSNB expertise (requires patent blue V dye injection + technetium-99m nanocolloid + gamma probe detection). Pelvic CT or MRI is used for regional staging. Preoperative penile MRI with prostaglandin-induced erection characterizes local tumor extent and corpus involvement for surgical planning. Sperm banking should be offered to patients of reproductive age before potentially sterilizing procedures.

Treatment is stratified by stage and location of disease. For carcinoma in situ (CIS/Tis) confined to the glans, laser ablation (neodymium:YAG or CO2 laser) or glansectomy with reconstruction is highly effective, with local recurrence rates of 10–20%. Topical therapies — 5-fluorouracil cream, imiquimod 5% cream, or photodynamic therapy — are alternatives for CIS, particularly for extensive or multi-focal lesions. For invasive stage T1a–T1b tumors (invading dermis or subepithelial connective tissue), organ-sparing procedures are preferred: wide local excision with reconstruction, Mohs micrographic surgery (for precisely defined margins), glansectomy, glansectomy with reconstruction using split-thickness skin graft, or distal penectomy with urethrostomy if adequate margins cannot be achieved. T2–T3 tumors (invading corpus cavernosum or urethra) require partial or total penectomy. Total penectomy with perineal urethrostomy removes the entire penile shaft and is curative for proximal tumors, with reported 5-year cancer-specific survival of 60–75%. Inguinal lymph node management is critical: invasive N0 disease (clinically node-negative) with T1b or higher grade requires dynamic sentinel lymph node biopsy (DSNLB) or modified inguinal lymph node dissection (mILND). Clinically positive inguinal nodes (N1–N2) undergo bilateral inguinal lymphadenectomy. Pelvic lymph node dissection is added for N3 disease. Neoadjuvant cisplatin-based chemotherapy (TPF: docetaxel, cisplatin, fluorouracil or BMP: bleomycin, methotrexate, cisplatin) is used for locally advanced nodal disease to downstage before surgery.

Organ-preserving surgery for early penile cancer (CIS through T1) achieves local recurrence rates of 10–25% — higher than amputation surgery but acceptable given the excellent salvage rates with secondary penectomy and the preserved quality of life. Glansectomy achieves 80–85% local control in T1 tumors with clear margins, with cosmetically and functionally acceptable outcomes in the majority of patients. Partial penectomy provides 95–98% local control for T2 disease when surgical margins are confirmed clear; sexual function (with a shorter but functional penis) is preserved in many patients. Five-year overall survival stratified by stage: stage I (T1N0M0) 85–90%, stage II (T2N0M0) 60–75%, stage III (node-positive T1–T3N1–N2M0) 30–50%, stage IV (T4 or N3 or M1) below 10%. Dynamic sentinel lymph node biopsy has a negative predictive value of 95% and avoids radical inguinal lymphadenectomy (with its 30–50% lymphedema complication) in 80% of cN0 patients. Neoadjuvant TIP chemotherapy (paclitaxel-ifosfamide-cisplatin) achieves objective response in 33–50% of patients with initially unresectable inguinal metastases, enabling curative resection in a proportion.

Organ-preserving procedures carry a local recurrence risk of 10–25% — significantly higher than partial (5–8%) or total penectomy (less than 5%) — requiring close urological follow-up with cystoscopy and biopsy at 3-month intervals for the first 2 years, then 6-monthly. Glansectomy with skin graft: graft failure (5–10%), meatal stenosis (10–15%), penile shortening, and altered sexual sensation. Partial penectomy: urethral stricture (10–15%), psychosexual distress, and altered voiding angle requiring a sitting void position. Total penectomy with perineal urethrostomy profoundly affects sexual function and body image, requiring multidisciplinary psychological support. Radical inguinal lymphadenectomy carries substantial morbidity: lymphedema of lower extremities (30–50%, often chronic and debilitating), wound infection and dehiscence (20–30%), skin necrosis (10–15%), deep vein thrombosis (5%), lymphocele (10–15%), and femoral nerve or vessel injury (rare). DSNB false-negative rate is 5–7%, meaning approximately 1 in 14–20 patients staged as node-negative harbors occult nodal disease not detected. TIP chemotherapy (paclitaxel, ifosfamide, cisplatin) causes significant toxicity: febrile neutropenia, peripheral neuropathy, nephrotoxicity, hemorrhagic cystitis (ifosfamide — requires MESNA prophylaxis), and alopecia.

Penile cancer surveillance is essential given a local recurrence risk of 10–25% after organ-sparing procedures. EAU guidelines recommend clinical examination of the primary site and inguinal regions every 3 months for 2 years, every 6 months through year 5, then annually. Self-examination education is critical for early detection of local recurrence. Imaging (CT chest, abdomen, pelvis or PET-CT) every 6 months for 2 years in node-positive disease detects regional and distant recurrence. MRI of the primary site may supplement clinical examination for ambiguous findings. After total penectomy, urethrostomy is assessed for stenosis and voiding function at each visit. Psychological support, sexual rehabilitation counselling, and discussion of reconstructive options (free-flap penile reconstruction) are integral to survivorship care. Patients with HPV-related disease should have partners assessed for mucosal HPV-related conditions, and HPV vaccination of eligible family members is recommended.

Penile cancer treatment costs depend significantly on stage, surgical approach, and whether inguinal dissection and systemic therapy are required. Glansectomy with skin graft reconstruction: India $3,000–7,000; USA $15,000–35,000; UK £8,000–20,000. Partial penectomy: India $4,000–10,000; USA $20,000–50,000. Total penectomy with perineal urethrostomy: India $5,000–12,000; USA $25,000–60,000. CO2/Nd:YAG laser ablation for CIS: India $1,500–4,000; USA $5,000–15,000. Radical inguinal lymphadenectomy (bilateral): India $5,000–12,000; USA $25,000–60,000. Dynamic sentinel lymph node biopsy (requiring nuclear medicine, gamma probe, and specialized surgical team): India $3,000–8,000; USA $15,000–35,000; UK £8,000–18,000 (not universally available). Neoadjuvant TIP chemotherapy (per cycle): India $500–2,000 (generics for ifosfamide and paclitaxel); USA $5,000–12,000. Total treatment package including surgery, staging, and 2 years of surveillance: India $8,000–20,000; USA $40,000–120,000. India's specialist oncourology centers in Mumbai, Chennai, and Hyderabad offer experienced surgical teams at substantially reduced international costs.

Organ-preservation strategies are strongly preferred over ablative surgery when oncologically safe. External beam radiotherapy (EBRT) or brachytherapy offers an alternative to penectomy for selected T1–T2 tumors up to 4 cm, with reported 5-year local control rates of 50–70% and preservation of sexual function in responders. Interstitial brachytherapy (iridium-192 implants) delivers high-dose radiation to the primary tumor with minimal surrounding tissue damage. However, radiation is associated with late complications including urethral stricture, penile necrosis, and telangiectasia, and local recurrence rates are higher than surgery. Topical imiquimod or 5-fluorouracil are appropriate for CIS and very superficial low-grade disease. Laser therapy (CO2 or Nd:YAG) ablates superficial CIS with excellent cosmetic outcomes, suitable for diffuse CIS or in situ disease not amenable to excision. For metastatic disease, cisplatin-based combination chemotherapy (TIP: paclitaxel, ifosfamide, cisplatin) is the most active regimen. Immunotherapy (pembrolizumab, nivolumab) has shown early activity in PD-L1-positive penile SCC, and clinical trials are expanding available options.